RRM1 Antibody

Code CSB-PA020518LA01HU
Size US$299Purchase it in Cusabio online store
(only available for customers from the US)
Image
  • Western blot
    All lanes: RRM1 antibody at 2µg/ml + Hela whole cell lysate
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 91 kDa
    Observed band size: 91 kDa
The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) RRM1 Polyclonal antibody
Uniprot No. P23921
Target Names RRM1
Alternative Names R1 antibody; Ribonucleoside diphosphate reductase large subunit antibody; Ribonucleoside diphosphate reductase M1 chain antibody; Ribonucleoside diphosphate reductase subunit M1 antibody; Ribonucleoside reductase; large subunit antibody; Ribonucleoside-diphosphate reductase large subunit antibody; Ribonucleoside-diphosphate reductase subunit M1 antibody; Ribonucleotide reductase large chain antibody; Ribonucleotide reductase large subunit antibody; Ribonucleotide reductase M1 antibody; Ribonucleotide reductase M1 polypeptide antibody; Ribonucleotide reductase R1 subunit antibody; Ribonucleotide reductase; M1 subunit antibody; RIR 1 antibody; RIR1 antibody; RIR1_HUMAN antibody; RR 1 antibody; RR1 antibody; RRM 1 antibody; RRM1 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Ribonucleoside-diphosphate reductase large subunit protein (1-792AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA, WB
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
Gene References into Functions
  1. The evaluation of RRM1 gene expression in cfRNA allows for estimation of the risk of severe oral mucositis (OM) in patients subjected to radiotherapy PMID: 29865035
  2. The expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. PMID: 29214667
  3. Our results therefore demonstrate that RRM1 is a novel therapeutic target in multiple myeloma in the preclinical setting and provide the basis for clinical evaluation of RRM1 inhibitor, alone or in combination with DNA-damaging agents, to improve patient outcome in multiple myeloma PMID: 28442502
  4. three SNPs (corepressor interacting with RBPJ 1 (CIR1) rs13009079T>C, ribonucleotide reductase M1 (RRM1) rs1465952T>C and solute carrier family 38, member 4 (SLC38A4) rs2429467C>T), may play a role in the pathogenesis of lung cancer PMID: 27587543
  5. TP53 mutant cancer cells had elevation of ribonucleotide reductase subunit 1 (RRM1) and 2 (RRM2), which was reduced by inhibition of mTORC1. PMID: 28507282
  6. The genetic polymorphisms RRM1 -756T>C and -269C>A may not be a factor for susceptibility to cervical neoplasia PMID: 27179014
  7. Based on the results of clinical trials, we conclude that Ribonucleotide reductase (RR) enzymes (RR1 and RR2)inhibitors are viable treatment options, either as a monotherapy or as a combination in cancer chemotherapy. With the recent advances made in cancer biology, further development of RR inhibitors with improved efficacy and reduced toxicity is possible for treatment of variety of cancers. PMID: 28624910
  8. RRM1 single nucleotide polymorphism is associated with Non-Small-Cell Lung Cancer. PMID: 27908619
  9. RRM1/RRM2B enzyme is capable of retaining activity in hypoxia and therefore is favored over RRM1/RRM2 in order to preserve ongoing replication and avoid the accumulation of DNA damage in hypoxic cells. PMID: 28416140
  10. findings suggest that the up-regulated RRM1 and hTrx1 in colorectal cancer directly interact with each other and promote RR activity, resulting in enhanced DNA synthesis and cancer malignancy. PMID: 28411237
  11. RRM1 and ERCC1 expression levels did not show any relationship with overall survival. PMID: 26612755
  12. RRM1 and ERCC wild type alleles are risk-reducing factor for Coronary artery disease (CAD). Also, carrying RRM1 A allele might have a protective effect for smokers. PMID: 27566080
  13. Presence of rare AA (-37C>A) and CC (-524C>T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in non-small cell lung cancer patients. PMID: 26650486
  14. study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I non-small cell lung cancer patients PMID: 26542178
  15. mRNA expression of RRM1 was closely associated with cell proliferation and varied in seven non-Hodgkin lymphoma cell lines. PMID: 27173327
  16. A significant association has been found between RRM1 rs12806698 (-269C>A) RRM1 genotype and the risk for developing non-small cell lung cancer. PMID: 26718430
  17. Results underline the relevance of microRNA-101-3p-driven regulation of RRM1 in pancreatic ductal carcinoma gemcitabine resistance. PMID: 26828016
  18. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer PMID: 26323924
  19. TUBB3, TOP2A, CYP19A1 and CYP2D6 gene expression, but not protein expression, was associated with patient survival. PMID: 26252353
  20. A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. PMID: 26637889
  21. RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy PMID: 26200905
  22. RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. PMID: 26083014
  23. It is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells. PMID: 25837929
  24. For RRM1 C37A-T524C genotype, sensitive group had higher proportion of high effective genotype than non-sensitive group (p=0.009). PMID: 26028097
  25. Adenoviral vector expressing short hairpin RNA targeting RRM1 exerts potent antitumor effects and increases sensitivity to gemcitabine. PMID: 26254808
  26. Data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance. PMID: 25497672
  27. These in vitro results suggest that mRNA expression levels of the RRM1 and ABCB1 genes may be useful indicators of chemosensitivity to gemcitabine and cisplatin. PMID: 25560468
  28. The oligomerization-directed fluorescence quenching of hRNR-alpha, covalently labeled with two fluorophores, allows for direct readout of hRNR dimeric and hexameric states. PMID: 25256246
  29. RRM1 expression was identified as independent prognosticators for freedom from recurrence of malignant pleural mesothelioma in patients undergoing induction chemotherapy followed by extrapleural pneumonectomy. PMID: 25840756
  30. In Turkish population RRM1 rs12806698 carriers have nearly twofold risk for development of head and neck squamous epithelial cell cancer. PMID: 24861915
  31. Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. PMID: 25078585
  32. Gene polymorphisms of RRM1 -756T>C and RRM1 -269C>A may be not an important factor for the susceptibility of breast cancer. PMID: 24578158
  33. concomitant low expression levels of ERCC1, RRM1, and RRM2 and the high expression level of BRCA1 were predictive of a better outcome. PMID: 25227663
  34. RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival in nonsmall cell lung cancer patients treated with gemcitabine plus cisplatin. PMID: 24591771
  35. RRM1 IHC expression tailored selection of first-line therapy could improve therapeutic outcomes in patients with advanced NSCLC. PMID: 24595080
  36. High intratumoural hENT1 and low RRM1 expression were independently associated with prolonged disease-free survival in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 25032731
  37. High RRM1 expression is associated with non-small cell lung cancer. PMID: 23803067
  38. No change in RRM1 expression was observed in primary NSCLC tumours, but expression seemed to be higher in N2 lymph node metastases following chemotherapy. PMID: 24266856
  39. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PMID: 23922955
  40. we found no support of the hypothesis that aberrations of RRM1 or RRM2B, neither individually nor in combination, are associated with an altered clinical outcome following chemotherapy. PMID: 24215511
  41. We observed an increase of ORR in NSCLC patients when they were treated with chemotherapy according to ERCC1 and RRM1 SNPs status. PMID: 24045016
  42. low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in non-small cell lung cancer PMID: 24155212
  43. RRM1 preserves chromosomal stability via the CHK1- and CDK1-dependent stabilization of the centrosomal integrity at the replication stage. PMID: 24434653
  44. Genetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of metastatic breast cancer patients treated with paclitaxel-gemcitabine chemotherapy. PMID: 24361227
  45. The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine PMID: 23982437
  46. These results suggest that SNPs within ribonucleotide reductase (RRM1 and RRM2) might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. PMID: 24024897
  47. Low RRM1 expression is associated with response to therapy in pancreatic cancer. PMID: 23991987
  48. RR1 expression may discriminate cervical cancer phenotype and radiochemotherapy outcome PMID: 23552804
  49. The expressions of MDR-1, RRM-1, EGFR, ERCC-1 were observed in a variety of pathological types of NSCLC. PMID: 23948418
  50. Report essential roles for ribonucleotide reductase and thymidylate synthase in C-MYC-dependent suppression of senescence in melanoma cells. PMID: 23249808
  51. The X-ray structure of two methylated tandem RRM domains (RRM1/2) of Hu antigen R (HuR) in their RNA-free form has been solved. Protein-RNA interactions designate RRM1 as the primary AU-rich element (ARE)-binding domain in HuR. PMID: 23519412
  52. RRM1 biomarkers may represent a major step toward biology-based prescription of cytotoxic compounds for lung neoplasms. PMID: 23401439
  53. The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced non-small cell lung cancer. PMID: 23086647
  54. We assessed the relation of mRNA levels of ERCC1, RRM1, and BRCA1 to survival in surgically-resected tumor tissues from patients who underwent adjuvant chemotherapy PMID: 23155271
  55. In postoperative NSCLC patients who are receiving adjuvant chemotherapy, patients with high expression of RRM1 tend to be resistant to gemcitabine. PMID: 20868593
  56. RRM1 levels in pancreatic ductal adenocarcinoma did not predict survival times in patients treated with adjuvant gemcitabine. PMID: 22705007
  57. The RRM1 2464 A/G, RRM1 37 C/C and RRM1 524 T/T alleles were associated with statistically significant superior progression free survival in pancreatic cancer patients receiving combination gemcitabine and sorafenib PMID: 21424698
  58. RRM1 polymorphisms as well as haplotypes showed an association with gemcitabine treatment efficacy and toxicity. PMID: 22134350
  59. ERCC1, RRM1 and BRCA1 are promising predictive and prognostic biomarkers in advanced non-small cell lung cancer. PMID: 20467918
  60. Single-nucleotide polymorphisms in RRM1 gene is associated with treatment response in non-small cell lung cancer. PMID: 21642870
  61. Data suggest ribonucleotide reductase A site binding with inhibitor. PMID: 21628579
  62. Cases with EGFR overexpression showed high expression of RRM1 and BRCA1 PMID: 21394302
  63. RRM1 -37A>C polymorphism may represent a useful biomarker to select mCRC patients most likely to benefit from gemcitabine-based salvage therapy. PMID: 21220199
  64. M1 (RRM1) expression in resected pancreatic cancer is not associated with OS or Pfs. PMID: 21264835
  65. RRM1 has a role in response to gemcitabine plus platinum therapy in advanced non-small-cell lung cancer PMID: 21370501
  66. The study reports the first X-ray structures of human RR1 bound to TTP alone, dATP alone, TTP-GDP, TTP-ATP, and TTP-dATP. PMID: 21336276
  67. RRM1, particularly in protein, level is a reliable marker for gemcitabine resistance in biliary tract carcinoma. PMID: 20811706
  68. Esophageal squamous cell carcinoma cells with a lower level of RRM1 expression are more sensitive to gemcitabine. PMID: 20021860
  69. RRM1 single nucleotide polymorphism is not associated with non-small cell lung cancer patients after gemcitabine-based chemotherapy. PMID: 20226083
  70. genetic polymorphisms is associated with sensitivity to platin-based chemotherapy in non-small cell lung cancer patients PMID: 19304340
  71. RRM1 suppression is an important step in increasing Gemcitabine efficacy PMID: 20043067
  72. Tip60-dependent recruitment of RNR plays an essential role in dNTP supply for DNA repair PMID: 20159953
  73. RRM1 levels influenced time to progression (P=0.05) and even more so, survival (P=0.0028) in the gemcitabine/cisplatin arm PMID: 12789263
  74. Susceptibility differences to RR inhibitors between hRRM1 and hRRM2 may lead to a new direction in drug design for human cancer treatment. PMID: 14729598
  75. The level of RRM1 may affect gemcitabine response in non-small cell lung cancer. Furthermore, RRM1 may serve as a biomarker for gemcitabine response. PMID: 15172981
  76. the binding site on RRM1 demonstrated higher affinity for RRM2 subunit than for p53R2 subunit PMID: 16376858
  77. overexpressed during the S phase of the cell cycle compared with the G0/1 phase PMID: 16476973
  78. Motexafin gadolinium induces enzymatic generation of reactive oxygen species by thioredoxin reductase and inhibits ribonucleotide reductase PMID: 16481328
  79. results strongly suggest that tumoral RRM1 expression is a major predictor of disease response to gemcitabine/platinum chemotherapy PMID: 16966686
  80. RRM1 could play a role in the prediction of patient outcome, and draw attention to the fact that response to gemcitabine. PMID: 17064812
  81. RRM1 RNA expression has a role in acquired resistance to gemcitabine PMID: 17065054
  82. RRM1 should be a key molecule in gemcitabine resistance in human pancreatic cancer. PMID: 17131328
  83. RRM1 haplotype showed an association with susceptibility to gemcitabine monotherapy in breast cancer patients. PMID: 17602053
  84. Ribonucleotide reductase subunit M1(RRM1) mRNA expression in lung adenocarcinoma is associated with clinical outcome of docetaxel/gemcitabine therapy. PMID: 18414411
  85. significant differences in response rates to gemcitabine-based chemotherapy according to the allelotypes of the RRM1 promoter sequence PMID: 18483375
  86. Significantly higher RRM1 mRNA expression was found in SCLC compared with NSCLC. There was no correlation between mRNA expression of the RRM1 gene and chemosensitivity to cisplatin, carboplatin or gemcitabine. PMID: 18494946
  87. Expression of RRM1 is associated with chemoresistance marker to gemcitabine in biliary tract carcinoma PMID: 18636187
  88. The mRNA expression of RRM1 is potentially a useful tool for selecting NSCLC patients for individualized chemotherapy PMID: 19002265
  89. Data show that the combination of RRM1 and ERCC1 expression is prognostic in pancreatic cancer patients after a complete resection. PMID: 19543324
  90. patients with advanced NSCLC treated with chemotherapy with gemcitabine and cisplatin appear to have a poor outcome if the tumor express elevated levels of RRM1 gene but surgical resection shows better survival. PMID: 19552012
  91. Clinical trial of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 20028759

Show More

Hide All

Subcellular Location Cytoplasm
Protein Families Ribonucleoside diphosphate reductase large chain family
Database Links

HGNC: 10451

OMIM: 180410

KEGG: hsa:6240

STRING: 9606.ENSP00000300738

UniGene: Hs.445705

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1